JPRN-UMIN000022996已完成未知
Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis
The Department of Cardiology, Nagoya University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2016年7月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patients with myelosuppression, chronic liver dysfunction, chronic kidney disease and infection.
研究者
相似试验
招募中
1 期
FDG-PET study for pulmonary MAC and CPAJPRN-jRCTs071190035Takazono Takahiro15
招募中
不适用
FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer.Esophageal cancerJPRN-UMIN000002249Osaka Medical Center for Cancer and Cardiovascular Diseases30
进行中（未招募）
不适用
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.Advanced stage Hodgkin's lymphomaMedDRA version: 15.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-005473-22-DKEORTC570
尚未招募
3 期
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research GroupAdvanced stage Hodgkin Lymphoma10025319NL-OMON39829European Organisation for Research in Treatment of Cancer (EORTC)190
进行中（未招募）
1 期
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.Advanced stage Hodgkin's lymphomaMedDRA version: 14.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-005473-22-BEEORTC570